HTR2A and hypertensive disorder: Furlotti et al. [110] reported the discovery and optimization of a series of novel 3,4-dihydropyrazino[1,2-b]indazol-1(2H)-one derivatives with the aim of developing new 5-hydroxytryptamine receptor 2A (5-HT2A) inhibitors for the treatment of hypertension.